Change in Ocular Flora Resistance From Repeated Topical Antibiotic Use
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01181713 |
Recruitment Status : Unknown
Verified December 2011 by Dr. Peter Kertes, Sunnybrook Health Sciences Centre.
Recruitment status was: Active, not recruiting
First Posted : August 13, 2010
Last Update Posted : December 5, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Increased Drug Resistance Infection Resistant to Quinolones and Fluoroquinolones |
Study Type : | Observational |
Estimated Enrollment : | 168 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Antibiotic Resistance of Ocular Surface Flora After Continued Use of Topical Antibiotics Post Intravitreal Injections |
Study Start Date : | June 2010 |
Estimated Primary Completion Date : | December 2012 |
Estimated Study Completion Date : | December 2012 |
Group/Cohort |
---|
No Antibiotic
No prophylactic antibiotic post intravitreal injection
|
Prophylactic Antibiotic
Group treated with 3 day course of prophylactic topic antibiotic, fourth generation fluoroquinolones, after each intravitreal injection
|
- ocular flora resistance to 4th generation fluoroquinolone [ Time Frame: 1 year ]Outcome will examine the change in amount, type and antibiotic resistance profile of ocular surface flora over the 3 months. Charcoal swab of the conjunctiva will be cultured, organisms grown will be identified and resistance to moxifloxacin will be quantified by minimal inhibitory resistance (MIC).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 65 Years and older (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- patients scheduled for intravitreal injection for neovascular age-related macular degeneration (ARMD)
- 65 years or older
- able to provide informed consent.
Exclusion Criteria:
- diagnosed with an active ocular, periocular or systemic infection
- previously received treatment with an intravitreal injection
- previously treated with antibiotics in the past three months
- unable to attend the scheduled follow-up appointments or to complete treatment for any reason

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01181713
Canada, Ontario | |
Sunnybrook Health and Sciences Centre | |
Toronto, Ontario, Canada, M4N 3M5 |
Study Chair: | Peter Kertes, MD, FRCSC | Sunnybrook Health Sciences Centre | |
Study Director: | Vivian T Yin, MD | University of Toronto | |
Study Director: | Daniel Weisbrod, MD, FRCSC | Sunnybrook Health Sciences Centre |
Responsible Party: | Dr. Peter Kertes, chief, department of ophthalmology, Sunnybrook Health Sciences Centre |
ClinicalTrials.gov Identifier: | NCT01181713 |
Other Study ID Numbers: |
SBK-OcuFResis |
First Posted: | August 13, 2010 Key Record Dates |
Last Update Posted: | December 5, 2011 |
Last Verified: | December 2011 |